Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thromboembolism 3Neoplasms 3Venous Thrombosis 2Thrombosis 2Pancreatic Neoplasms 2Thromboembolism 1Stomach Neoplasms 1Pulmonary Embolism 1Ovarian Neoplasms 1Obesity 1Multiple Myeloma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Embolism and Thrombosis 1Embolism 1Duodenal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

alvocidib 1Warfarin 1Ketoconazole 1Gemcitabine 1Fondaparinux 1Estramustine 1Doxorubicin 1Docetaxel 1Dalteparin 1Clopidogrel 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thromboembolism × Dalteparin × Clear all
NCT00462852 2013-08-12

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡